Baltimore-Based CSA Medical Raises $20.5 Million in Second Round
Baltimore, Maryland – CSA Medical, a provider of cryotherapy systems and offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues has raised $20.5 M of series B funding from InterSouth Funding and First Analysis and backed up by S.V. Life Sciences, Rose Park, Blue Heron Capital and other existing investors from its January round of funding.
Aside from the new funding, CSA Medical also announced that Tracy Marshbanks from First Analysis, Dr. Rick Kent of Intersouth Partners, and Paul LaViolette from S.V. Life Sciences will join the CSA’s board of directors.
“CSA’s platform technology has the potential to revolutionize current approaches to the treatment of multiple disease states for which there is clearly an unmet clinical need,” noted Rick Kent, partner at Intersouth Partners. “The company has already demonstrated an ability to bring novel medical devices through development and into the market, as evidenced by its progress in the gastrointestinal space, and we are pleased to support their efforts to address new applications for Spray Cryotherapy.”
The new funding will be used on on new marketing strategies, research and studies and also to fund and support new development of products and continuing the success of the company’s Spray Cryotherapy system.
Visit CSA Medical for more details:
